---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-071769"
form_type: "8-K"
ticker: "ANIP"
cik: "0001023024"
company_name: "ANI PHARMACEUTICALS INC"
filed_at: "2025-07-29T23:59:59+00:00"
generated_at: "2026-05-17T23:29:16.521744+00:00"
event_type: "litigation"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ANI Pharmaceuticals loses jury verdict in royalty dispute with CG Oncology; no damages awarded

## Summary
- Jury returned verdict on July 29, 2025 awarding no damages to ANI on its unjust enrichment counterclaim against CG Oncology.
- Court previously granted CG Oncology's partial summary judgment on Brulotte defense, finding royalty provision unenforceable.
- ANI intends to challenge the verdict through post-trial motions and/or an appeal.
- Case stems from a 2010 Agreement for a 5% royalty on worldwide net sales of cretostimogene.

## SEC filing metadata
- accession: 0001104659-25-071769
- form_type: 8-K
- ticker: ANIP
- cik: 0001023024
- company_name: ANI PHARMACEUTICALS INC
- filed_at: 2025-07-29T23:59:59+00:00
- event_type: litigation
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1023024/000110465925071769/0001104659-25-071769-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1023024/000110465925071769/tm2522000d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-071769
- JSON: https://secwatch.observer/filing/0001104659-25-071769.json
- Plain text: https://secwatch.observer/filing/0001104659-25-071769.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.